Company page

Globeimmune Inc

Globeimmune Inc, trading under the ticker GBIM, is a public company based in the United States with a market capitalization of $575 million. The company focuses on developing innovative immunotherapies for cancer and infectious diseases. Globeimmune aims to leverage its proprietary technology to advance treatment options and improve patient outcomes.